Search
for

    Glossary Phosphodiesterase

    enzyme that breaks down cyclic nucleotides in cells

    Phosphodiesterase (PDE) is an enzyme that plays a crucial role in cellular signaling by breaking down cyclic nucleotides like cAMP and cGMP, which are molecules that transmit signals inside cells. By regulating the levels of these cyclic nucleotides, PDEs help control various physiological processes, including heart rate, inflammation, and even hair growth.

    Related Terms

    Sort by

    Research 30 of 535

    1. The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms Journal of Dermatological Science · 2018 · 21 citations
    2. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors 2022 · 12 citations
    3. Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata European Journal of Dermatology · 2019 · 10 citations
    4. Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review Dermatologic Therapy · 2020 · 9 citations
    5. The use of phosphodiesterase inhibitors for the treatment of alopecia Journal of Dermatological Treatment · 2019 · 3 citations
    6. Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors? Journal of The European Academy of Dermatology and Venereology · 2020 · 1 citations
    7. The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth Seoul National University Open Repository (Seoul National University) · 2020 · 1 citations
    8. 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration Journal of Investigative Dermatology · 2024
    9. 467 Novel selective phosphodiesterase inhibitors promote the adipogenic function of dermal fibroblasts: Implication to treat hair loss Journal of Investigative Dermatology · 2021
    10. PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION The Journal of Urology · 2018
    11. Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions Springer eBooks · 2018
    12. Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor Medicina Clínica (english Edition) · 2023
    13. White Lupin Cluster Root Acclimation to Phosphorus Deficiency and Root Hair Development Involve Unique Glycerophosphodiester Phosphodiesterases Plant physiology · 2011 · 80 citations
    14. Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations Andrology · 2005 · 280 citations
    15. Alopecia areata Journal of the American Academy of Dermatology · 2017 · 182 citations
    16. Caffeine’s Mechanisms of Action and Its Cosmetic Use Skin Pharmacology and Physiology · 2012 · 153 citations
    17. Adverse effects of common medications on male fertility Nature Reviews Urology · 2015 · 77 citations
    18. INTERACTION OF α-MELANOCYTE-STIMULATING HORMONE, MELATONIN, CYCLIC AMP AND CYCLIC GMP IN THE CONTROL OF MELANOGENESIS IN HAIR FOLLICLE MELANOCYTES IN VITRO Journal of Endocrinology · 1981 · 53 citations
    19. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Frontiers in Pharmacology · 2020 · 35 citations
    20. Risks and side effects in the medical management of benign prostatic hyperplasia Prostate International · 2023 · 26 citations
    21. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases 2017 · 25 citations
    22. Lack of efficacy of apremilast in 9 patients with severe alopecia areata Journal of the American Academy of Dermatology · 2017 · 23 citations
    23. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss Pharmacotherapy · 2016 · 19 citations
    24. Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation Theranostics · 2021 · 18 citations
    25. Insights learned from L457(3.43)R, an activating mutant of the human lutropin receptor Molecular and Cellular Endocrinology · 2006 · 17 citations
    26. 5-Alpha-Reductase Inhibitors and Combination Therapy Urologic Clinics of North America · 2016 · 15 citations
    27. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs Pharmacopsychiatry · 2015 · 15 citations
    28. Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia Current Medicinal Chemistry · 2006 · 14 citations
    29. Effect of a transcriptional inactive or absent vitamin D receptor on beta-cell function and glucose homeostasis in mice 2016 · 13 citations
    30. Role of caffeine in the management of androgenetic alopecia International Journal of Trichology · 2012 · 11 citations